Hospital
Monmouth Medical Center INC
Monmouth Medical Center INC was paid $110.02M by Medicaid between Jan 2018 and Dec 2024, across 405 billing codes. Its largest line is G0378, Hospital observation service, per hour — 14% of everything it billed.
33Billing provider infoMONMOUTH MEDICAL CENTER INC
LONG BRANCH, NJ 07740
LONG BRANCH, NJ 07740
33aNPI1609983790assigned 08/24/2006
33bProvider typePsychiatric Hospital Unit
28Total paid$110.02M
24GClaims1,179,035
24DCodes billed405
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in New Jersey
Rank by total paid#1 of 12
Median peer was paid$1.26M
This provider vs. median88×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 172,661 | $16.30M | |
| 2019 | 174,293 | $15.51M | |
| 2020 | 124,710 | $10.91M | |
| 2021 | 155,200 | $15.72M | |
| 2022 | 204,002 | $16.80M | |
| 2023 | 198,285 | $17.52M | |
| 2024incomplete | 149,884 | $17.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 14% | 16,631 | 14,169 | $15.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 40,302 | 37,375 | $14.99M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 28,868 | 26,451 | $11.74M |
| T2034 | Crisis intervention, waiver; per diem | 6.7% | 8,618 | 7,644 | $7.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 16,830 | 15,185 | $7.06M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.6% | 2,067 | 2,025 | $5.04M |
| OP250 | 3.6% | 95,214 | 53,803 | $3.98M | |
| S9480 | Intensive outpatient psychiatric services, per diem | 2.8% | 3,837 | 3,510 | $3.06M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 8,815 | 8,389 | $2.29M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.9% | 4,331 | 2,439 | $2.06M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.6% | 9,286 | 941 | $1.76M |
| 80053 | Comprehensive metabolic panel | 1.4% | 51,719 | 41,759 | $1.58M |
393 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 1,772 | $1.55M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 825 | $1.49M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 7,422 | $921K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,505 | $898K |
| OP370 | <1% | 9,720 | $891K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,598 | $871K |
| 96367 | <1% | 2,804 | $861K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,325 | $737K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,194 | $732K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,758 | $653K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 11,641 | $636K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 18,062 | $561K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,199 | $549K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 9,773 | $506K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,766 | $501K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,927 | $480K |
| OP710 | <1% | 10,016 | $476K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,735 | $473K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,678 | $470K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,623 | $458K |
| 90837 | Psychotherapy session, about an hour | <1% | 6,213 | $439K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 5,523 | $435K |
| 76642 | <1% | 2,594 | $425K | |
| 93017 | <1% | 818 | $422K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,535 | $377K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,656 | $375K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 19,114 | $371K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 16,206 | $369K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,958 | $366K |
| 36415 | Collection of venous blood by venipuncture | <1% | 62,072 | $365K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,961 | $345K |
| 95714 | <1% | 162 | $321K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,536 | $319K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,807 | $314K |
| J2426 | Injection, paliperidone palmitate extended release (invega sustenna), 1 mg | <1% | 498 | $308K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,250 | $306K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 308 | $303K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,416 | $299K |
| OP272 | <1% | 11,788 | $294K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,840 | $289K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,549 | $285K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,441 | $285K |
| 76830 | Ultrasound, transvaginal | <1% | 2,241 | $249K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,926 | $235K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 4,442 | $234K |
| 93975 | <1% | 630 | $225K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 4,569 | $217K |
| 76820 | <1% | 1,128 | $202K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,170 | $199K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,808 | $180K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 3,105 | $180K |
| 95700 | <1% | 971 | $179K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 418 | $177K |
| 77065 | Tomosynthesis, mammo | <1% | 1,642 | $174K |
| OP258 | <1% | 37,005 | $173K | |
| 76770 | <1% | 1,203 | $170K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,839 | $166K |
| 86850 | <1% | 6,888 | $163K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,070 | $159K |
| 80061 | Lipid panel | <1% | 6,507 | $157K |
| 73560 | <1% | 2,715 | $156K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 285 | $156K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,393 | $154K |
| 76536 | <1% | 947 | $149K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,710 | $143K |
| 73110 | <1% | 1,873 | $137K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,341 | $135K |
| 96417 | <1% | 416 | $134K | |
| 73630 | <1% | 2,302 | $133K | |
| 73130 | <1% | 2,224 | $131K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,712 | $129K |
| 77080 | <1% | 876 | $128K | |
| J0401 | Injection, aripiprazole (abilify maintena), 1 mg | <1% | 277 | $127K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,689 | $124K |
| 87081 | <1% | 6,068 | $123K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,100 | $122K |
| 93971 | <1% | 868 | $119K | |
| 82962 | <1% | 13,717 | $118K | |
| 81001 | <1% | 17,373 | $118K | |
| 76813 | <1% | 917 | $117K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 226 | $114K |
| 97802 | <1% | 936 | $113K | |
| 96415 | <1% | 329 | $113K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 613 | $112K |
| 73030 | <1% | 1,735 | $112K | |
| 73610 | <1% | 2,370 | $110K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 1,383 | $107K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,363 | $105K |
| 72110 | <1% | 842 | $104K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,547 | $100K |
| 59820 | <1% | 39 | $89K | |
| 71250 | <1% | 505 | $88K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,851 | $86K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,057 | $83K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 336 | $81K |
| 93970 | <1% | 325 | $78K | |
| 95708 | <1% | 80 | $77K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 26 | $74K |
| 95713 | <1% | 73 | $72K | |
| 76641 | <1% | 285 | $71K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,422 | $70K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,603 | $69K |
| 87040 | <1% | 5,753 | $68K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,007 | $66K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 170 | $63K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,017 | $61K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 961 | $59K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 805 | $58K |
| 72100 | <1% | 1,353 | $56K | |
| 95800 | <1% | 65 | $54K | |
| C1776 | Joint device (implantable) | <1% | 12 | $53K |
| 73590 | <1% | 672 | $53K | |
| 74022 | <1% | 895 | $52K | |
| 86900 | <1% | 7,006 | $52K | |
| 83655 | <1% | 1,367 | $51K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,053 | $49K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,807 | $49K |
| 10060 | <1% | 55 | $47K | |
| 85027 | <1% | 8,830 | $44K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,837 | $44K |
| 84439 | <1% | 3,043 | $43K | |
| 99205 | Prolong outpt/office vis | <1% | 252 | $41K |
| 87070 | <1% | 1,840 | $40K | |
| 82542 | <1% | 1,312 | $39K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,057 | $39K |
| 87807 | <1% | 1,737 | $38K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,454 | $38K |
| 76801 | <1% | 519 | $37K | |
| 73080 | <1% | 765 | $36K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 266 | $36K |
| 72050 | <1% | 332 | $35K | |
| A9270 | Non-covered item or service | <1% | 13,108 | $35K |
| 83880 | <1% | 3,686 | $34K | |
| 96376 | <1% | 4,024 | $34K | |
| 84484 | <1% | 8,041 | $33K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 370 | $32K |
| 73502 | <1% | 977 | $32K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 201 | $32K |
| 82728 | <1% | 1,929 | $31K | |
| 81003 | <1% | 9,132 | $31K | |
| 73090 | <1% | 515 | $30K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 552 | $30K |
| 85610 | <1% | 6,879 | $30K | |
| 74018 | <1% | 622 | $29K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 218 | $29K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 10,235 | $29K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 124 | $29K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,197 | $28K |
| 97803 | <1% | 346 | $27K | |
| 86901 | <1% | 7,161 | $27K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,553 | $26K |
| OP278 | <1% | 124 | $26K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 285 | $26K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 468 | $25K |
| 92587 | <1% | 113 | $25K | |
| 59025 | Fetal non-stress test | <1% | 117 | $24K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 242 | $24K |
| 83735 | <1% | 6,295 | $24K | |
| 85007 | <1% | 5,178 | $23K | |
| 73562 | <1% | 314 | $22K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 48 | $22K |
| 36430 | <1% | 55 | $22K | |
| 85730 | <1% | 5,834 | $20K | |
| 86703 | <1% | 896 | $20K | |
| 20610 | <1% | 30 | $20K | |
| J2704 | Injection, propofol, 10 mg | <1% | 7,969 | $19K |
| 76870 | <1% | 161 | $19K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,084 | $17K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 30 | $17K |
| 86592 | <1% | 1,096 | $17K | |
| 83690 | <1% | 8,841 | $16K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 107 | $16K |
| 82248 | <1% | 4,377 | $15K | |
| 81025 | <1% | 2,947 | $15K | |
| 77336 | <1% | 82 | $15K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 376 | $14K |
| 93351 | <1% | 12 | $13K | |
| 86141 | <1% | 1,542 | $13K | |
| 12001 | <1% | 169 | $13K | |
| 36591 | <1% | 164 | $13K | |
| 82247 | <1% | 1,004 | $13K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,254 | $13K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,221 | $12K |
| 82607 | <1% | 1,029 | $12K | |
| 83550 | <1% | 1,399 | $12K | |
| 84702 | <1% | 1,807 | $11K | |
| G0270 | Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes | <1% | 83 | $11K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $11K |
| 76937 | <1% | 57 | $11K | |
| 97166 | <1% | 186 | $11K | |
| 86140 | <1% | 7,193 | $11K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 148 | $10K |
| 83540 | <1% | 1,465 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,532 | $10K |
| 74183 | <1% | 12 | $10K | |
| 87186 | <1% | 1,218 | $10K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 182 | $10K |
| 83021 | <1% | 414 | $10K | |
| 84156 | <1% | 1,543 | $9K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,182 | $9K |
| 82951 | <1% | 302 | $9K | |
| 0001A | <1% | 243 | $9K | |
| 83605 | <1% | 1,458 | $9K | |
| 87088 | <1% | 1,897 | $9K | |
| 86803 | <1% | 472 | $9K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,976 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 594 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,461 | $8K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 62 | $8K |
| 0002A | <1% | 213 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,043 | $8K |
| 99201 | <1% | 151 | $8K | |
| 87486 | <1% | 1,193 | $7K | |
| 82731 | <1% | 30 | $7K | |
| G0008 | Administration of influenza virus vaccine | <1% | 431 | $7K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 177 | $7K |
| 82043 | <1% | 552 | $7K | |
| 87077 | <1% | 1,650 | $7K | |
| 82570 | <1% | 1,756 | $6K | |
| 85651 | <1% | 2,746 | $6K | |
| 85044 | <1% | 1,665 | $6K | |
| 84460 | <1% | 257 | $6K | |
| 76821 | <1% | 37 | $6K | |
| 87581 | <1% | 1,193 | $6K | |
| 73140 | <1% | 98 | $6K | |
| 83615 | <1% | 1,475 | $6K | |
| 12011 | <1% | 53 | $6K | |
| 97162 | <1% | 108 | $6K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,083 | $6K |
| 85045 | <1% | 1,850 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,513 | $5K |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 27 | $5K |
| 82150 | <1% | 2,609 | $5K | |
| 88304 | <1% | 773 | $5K | |
| 88312 | <1% | 392 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | $4K |
| 88313 | <1% | 184 | $4K | |
| 76882 | <1% | 29 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 890 | $4K |
| 89230 | <1% | 105 | $4K | |
| 84100 | <1% | 2,165 | $4K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 131 | $4K |
| 96401 | <1% | 31 | $4K | |
| 84436 | <1% | 415 | $4K | |
| 90686 | <1% | 190 | $4K | |
| 84480 | <1% | 329 | $4K | |
| 80320 | <1% | 559 | $3K | |
| 86480 | <1% | 68 | $3K | |
| 82550 | <1% | 1,140 | $3K | |
| 84550 | <1% | 643 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,410 | $3K |
| 82950 | <1% | 147 | $3K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 202 | $3K |
| 88342 | <1% | 176 | $3K | |
| C7901 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 296 | $3K |
| 87147 | <1% | 435 | $3K | |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 121 | $3K |
| 82746 | <1% | 227 | $3K | |
| 86664 | <1% | 92 | $3K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,422 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,556 | $3K |
| 84145 | <1% | 235 | $3K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 110 | $3K |
| 87205 | <1% | 1,749 | $3K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 17 | $3K |
| OP255 | <1% | 949 | $3K | |
| 92579 | <1% | 14 | $2K | |
| 73700 | <1% | 13 | $2K | |
| 80055 | <1% | 40 | $2K | |
| 29125 | <1% | 167 | $2K | |
| 74019 | <1% | 39 | $2K | |
| 70360 | <1% | 36 | $2K | |
| 80074 | <1% | 100 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 16 | $2K |
| 90715 | <1% | 519 | $2K | |
| C1769 | Guide wire | <1% | 246 | $2K |
| 85014 | <1% | 417 | $2K | |
| 0004A | <1% | 52 | $2K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 17 | $2K |
| 87430 | <1% | 94 | $2K | |
| 96368 | <1% | 24 | $2K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 493 | $2K |
| OP270 | <1% | 815 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 153 | $2K |
| 84153 | <1% | 102 | $2K | |
| 92555 | <1% | 13 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 212 | $2K |
| 86920 | <1% | 14 | $1K | |
| 85652 | <1% | 670 | $1K | |
| 73060 | <1% | 25 | $1K | |
| 85378 | <1% | 1,020 | $1K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 38 | $1K |
| 86617 | <1% | 73 | $1K | |
| 97161 | <1% | 77 | $1K | |
| 85018 | <1% | 356 | $1K | |
| OP637 | <1% | 1,175 | $1K | |
| 73552 | <1% | 28 | $1K | |
| 0054A | <1% | 35 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 697 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 44 | $1K |
| 29515 | <1% | 153 | $1K | |
| 73070 | <1% | 28 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 104 | $970.24 |
| 87046 | <1% | 85 | $964.19 | |
| 86308 | <1% | 178 | $933.49 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,313 | $898.32 |
| 85041 | <1% | 273 | $845.33 | |
| 86665 | <1% | 92 | $783.27 | |
| 82784 | <1% | 27 | $770.71 | |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | <1% | 13 | $750.00 |
| 82947 | <1% | 334 | $748.01 | |
| 90662 | <1% | 49 | $709.58 | |
| 87045 | <1% | 70 | $705.28 | |
| 73522 | <1% | 12 | $697.12 | |
| 87075 | <1% | 196 | $653.36 | |
| J1815 | Injection, insulin, per 5 units | <1% | 329 | $641.34 |
| 0064A | <1% | 18 | $640.00 | |
| 75571 | <1% | 93 | $619.24 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 725 | $611.44 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 38 | $604.26 |
| 85380 | <1% | 206 | $594.26 | |
| C7900 | Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 15-29 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service | <1% | 217 | $513.60 |
| 0011A | <1% | 15 | $489.53 | |
| 0072A | <1% | 12 | $480.00 | |
| 0071A | <1% | 12 | $480.00 | |
| 82105 | <1% | 12 | $469.54 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 618 | $463.62 |
| 82565 | <1% | 386 | $459.61 | |
| 88341 | <1% | 12 | $442.84 | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 13 | $404.98 |
| 82310 | <1% | 338 | $377.80 | |
| 82378 | <1% | 29 | $341.36 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 12 | $336.84 |
| 84295 | <1% | 286 | $331.64 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 30 | $314.37 |
| 85008 | <1% | 603 | $295.42 | |
| 87400 | <1% | 75 | $277.28 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 397 | $277.05 |
| 88185 | <1% | 13 | $269.51 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 404 | $259.14 |
| 84520 | <1% | 294 | $253.92 | |
| 82374 | <1% | 284 | $237.59 | |
| 84075 | <1% | 209 | $232.24 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 234 | $231.85 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 18 | $222.32 |
| 82435 | <1% | 284 | $221.59 | |
| 88302 | <1% | 38 | $210.40 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 124 | $207.93 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 464 | $191.79 |
| 84450 | <1% | 237 | $190.58 | |
| 80179 | <1% | 82 | $177.20 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 837 | $151.71 |
| 87493 | <1% | 39 | $150.99 | |
| 84155 | <1% | 264 | $129.66 | |
| 82040 | <1% | 221 | $128.16 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 106 | $113.27 |
| 80143 | <1% | 29 | $95.19 | |
| 86431 | <1% | 13 | $92.34 | |
| 82438 | <1% | 62 | $85.31 | |
| 87340 | <1% | 39 | $83.79 | |
| 84703 | <1% | 95 | $72.01 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 139 | $68.40 |
| 88300 | <1% | 12 | $57.53 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 39 | $52.22 |
| 90656 | <1% | 14 | $49.42 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 17 | $46.88 |
| 84481 | <1% | 15 | $45.00 | |
| 82010 | <1% | 28 | $44.76 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 41 | $32.44 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 81 | $29.05 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 51 | $22.13 |
| 82274 | <1% | 67 | $15.92 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 12 | $15.66 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 32 | $14.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 71 | $13.28 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 19 | $12.49 |
| 87427 | <1% | 56 | $12.18 | |
| 87899 | <1% | 56 | $12.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 12 | $6.60 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 55 | $5.21 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 35 | $4.16 |
| 91300 | <1% | 173 | $3.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 115 | $2.00 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 12 | $1.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 31 | $0.03 |
| 84132 | 0% | 29 | $0.00 | |
| 72040 | 0% | 14 | $0.00 | |
| 97165 | 0% | 13 | $0.00 | |
| 91301 | 0% | 13 | $0.00 | |
| 80329 | 0% | 13 | $0.00 | |
| 91305 | 0% | 16 | $0.00 | |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | 0% | 56 | $0.00 |
| 71100 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARNEY, ERIC (CEO)
Parent organizationRWJ BARNABAS HEALTH INC
| Provider | Location | Paid |
|---|---|---|
| Monmouth Medical Center INC | Lakewood, NJ | $60.14M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.